Consensus statement on the use of botulinum neurotoxin to treat spasticity in adults

P and T

Volumn 31, Issue 11, 2006, Pages

  Davis, Thomas L ^a   Brodsky, Matthew A ^b   Carter, Victoria A ^c   DiFazio, Marc ^d,e   Frishberg, Ben ^f,g   Lai, Eugene C ^h,i   McGuire, John ^j   Meyer, Douglas P ^m   Ostrem, Jill L ^k,l   Sarwar, Aliya I ^h,i   White, Kevin ^j  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d Capital Neurology Associates   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^f Neurology Center   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m Douglas Meyer Pharmacy Services Consulting   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ASHWORTH SCALE; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; DISABILITY; DISABILITY ASSESSMENT SCALE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ELECTROMYOGRAPHY; FUGL MEYER SCALE; FUNCTIONAL INDEPENDECE MEASURE; HEMATOMA; HUMAN; INJECTION SITE PAIN; MUSCLE TONE; PHYSICIAN AND PATIENT GLOBAL ASSESSMENT SCALE; RAND 36 ITEM HEALTH SURVEY 1.0; RATING SCALE; SCORING SYSTEM; SPASTICITY; STROKE; TREATMENT OUTCOME; XEROSTOMIA;

EID: 33845216007     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Gracies JM, Hefter H, Simpson DM, Moore P. Spasticity in adults. In: Moore P, Neumann M, eds. Handbook of Botulinum Toxin Treatment, 2nd ed. Oxford, UK: Blackwell Science Ltd; 2003:219-271.
2. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motor neuron lesion. In: Mayer NH, Simpson DM, eds. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. New York, NY: WE MOVE; 2002:1-10.
3. Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl 1997;6:S208-S220.
4. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 1986;26:427-453.
5. Aoki KR. Pharmacology of botulinum neurotoxins. Oper Tech Otolaryngol Head Neck Surg 2004;15(2):81-85.
6. Centre for Evidence-Based Medicine. Levels of Evidence and Grades of Recommendation. Available at: www.cebm.net/levels_of_evidence.asp. Accessed November 11, 2005.
7. Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: A double-blind study. Ann Neurol 1990;28(4):512-515.
8. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45(4):712-717.
9. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial. Neurology 1996;46(5):1306-1310.
10. Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: A randomized, double-blind trial. Am J Phys Med Rehabil 1998;77(6):510-515.
11. Richardson D, Sheean G, Werring D, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000;69(4):499-506.
12. Brashear A, Gordon MF, Elovic E, et al, for the Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347(6):395-400.
13. Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb post-stroke spasticity: A double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004;85(5):705-709.
14. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004;85(7):1063-1069.
15. Verplancke D, Snape S, Salisbury CF, et al. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005;19(2):117-125.
16. Pai M, McColloch M, Gorman JD, et al. Systematic reviews and meta-analyses: An illustrated, step-by-step guide. Natl Med J India 2006;17:86-95.
17. The WE MOVE Spasticity Study Group. Dosing, administration, and treatment algorithm. In: Mayer NH, Simpson DM, eds. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. New York, NY: WE MOVE; 2002:154-165.